自拟参附贞芪汤联合利伐沙班治疗慢性心衰的临床疗效研究

Abstract
Figure/Table
References
Related Citation (5)

Download: PDF (2281 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observed the clinical effect of self-proposed Shenfu Zhenqi Tang combined with rivaroxaban in treating chronic heart failure. Methods 80 patients with chronic heart failure were randomly divided into the control group and the observation group, and the control group received conventional treatment + rivaroxaban treatment. The observation group received conventional treatment + rivaroxaban. The observation group was treated with self-proposed Shenfu Zhenqi Tang based on the control group. The two groups were compared regarding improvement of major clinical symptoms, serum NT-pro BNP level, 6-min walking distance, improvement of cardiac function, and therapeutic effect. Results The disappearance time of clinical symptoms such as palpitation and shortness of breath in the observation group was shorter than in the control group. There was no statistically significant difference between the two groups in the disappearance time of clinical symptoms such as facial limb swelling, dry mouth, shortness of breath, chest tightness, and cough. The serum NT-pro BNP level after treatment in the observation group was lower than that in the control group. The 6-minute walking distance after treatment in the observation group was much longer than that in the control group. After treatment, LVESD, LVEDD, and LVRT of the observation group were significantly lower than those of the control group, and EF was significantly higher than that of the control group. The total effective rate after treatment in the observation group was higher than in the control group. Conclusion Self-designed Shenfu Zhenqi Tang combined with rivaroxaban in treating of chronic heart failure can reduce clinical symptoms, lower plasma NT-pro BNP level, increase 6-minute walking distance, improve myocardial function, and be suitable for clinical application.

Key words： Shenfu Zhenqi Tang rivaroxaban chronic heart failure clinical effect

Received: 07 September 2023

PACS:

R541.6

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GUO Xiaoyang
	HE Yue
	DENG Xiaoxiu
	PAN Qingdeng
	BAO Huixian

Cite this article:

GUO Xiaoyang,HE Yue,DENG Xiaoxiu等. Study on the clinical effect of self-proposed Shenfu Zhenqi Tang combined with rivaroxaban in the treatment of chronic heart failure[J]. HuNan ShiFan DaXue XueBao(YiXueBan), 2023, 20(6): 70-72.

URL:

http://yxb.hunnu.edu.cn/EN/ OR http://yxb.hunnu.edu.cn/EN/Y2023/V20/I6/70

[1] 上官秋圆, 董璐怡. 沙库巴曲缬沙坦治疗慢性心力衰竭患者预后的影响因素分析[J]. 中华老年心脑血管病杂志, 2023, 25(7): 708-711.
[2] MCDONAGH TA, METRA M, ADAMO M, et al.2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42(36): 3599-3726.
[3] 张嘉嘉. 利伐沙班治疗非瓣膜性心房颤动患者抗凝效果与安全性观察[J]. 中国处方药, 2023, 21(7): 137-139.
[4] 蒙延海, 张燕搏, 刘平, 等. 《2022 AHA/ACC/HFSA心力衰竭管理指南》解读: 心力衰竭新理念和心外科关注点[J]. 中国胸心血管外科临床杂志, 2022, 29(6): 676-683.
[5] 陈家旭, 邹小娟. 中医诊断学[M]. 北京: 人民卫生出版社, 2021: 127-129.
[6] 葛乐品, 姜祖超, 陈鹏鹏, 等. 补阳还五汤联合抗阻训练治疗气虚血瘀型慢性心力衰竭的临床探究[J]. 全科医学临床与教育, 2023, 21(7): 596-599.
[7] 张晨曦, 梁雪梅, 张秀芹, 等. 金匮肾气丸联合沙库巴曲缬沙坦对慢性心力衰竭患者的影响[J]. 心脏杂志, 2023, 35(6): 680-684.
[8] 杨乾方, 王帆, 潘立民, 等. 人参皂苷Rg₃提取制备、化学结构及其药理作用的研究进展[J]. 辽宁中医药大学学报, 2023, 25(12): 196-202.
[9] 徐敬娅, 张春蕾, 李宝龙. 基于网络药理学和实验验证探讨参附汤对心源性休克的作用机制[J]. 中国药理学通报, 2023, 39(8): 1548-1557.
[10] 姜卓, 周洁, 杨爱祥, 等. 新活素注射液联合速尿治疗难治性心力衰竭疗效及对心功能血气指标和血清NT-pro BNP PCT水平的影响[J]. 河北医学, 2023, 29(3): 402-406.
[11] 陈文威, 陈淼林. 托伐普坦联合沙库巴曲缬沙坦钠对慢性心衰患者血清NT-pro BNP水平及心功能的影响[J]. 黑龙江医学, 2022, 46(11): 1355-1357.
[12] 李瑾, 刘江峰, 符赵鑫. 沙库巴曲缬沙坦钠联合呋塞米、地高辛对慢性心衰患者心功能及血清炎性因子水平的影响[J]. 华夏医学, 2021, 34(5): 94-98.
[13] 杨柳, 叶东, 胡耀, 等. 参附注射液基于TLRs信号通路对慢性心力衰竭大鼠模型保护作用的机制研究[J]. 中国中医药现代远程教育, 2023, 21(13): 134-137.
[14] 廖晓倩, 黄淑敏, 范星宇, 等. 基于PI3K/Akt/mTOR通路探讨参附注射液调控自噬对慢性心力衰竭大鼠的保护作用[J/OL]. 中国中药杂志, 2023, 48(21): 5908-5914.